The advent of CFTR modulators, a genomic specific medication, revolutionized the treatment
of CF for many patients. However, given that these therapeutics were only developed for …

Small molecular modulators of the cystic fibrosis transmembrane conductance regulator
protein are transforming the care of people with cystic fibrosis. Highly effective modulators …

Background Many individuals with cystic fibrosis (CF) have chronic rhinosinusitis resulting in
nasal obstruction, sinus infections, and repeated surgeries. Elexacaftor-tezacaftor-ivacaftor …

Abstract Background Therapy with Elexacaftor/Tezacaftor/Ivacaftor (ETI) was recently
approved for adult cystic fibrosis (CF) patients with at least one F508del mutation. However …

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR), which lead to early death due to progressive lung disease. The …

Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic
variants in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR …

Rationale: Elexacaftor, tezacaftor, and ivacaftor (ETI) in triple combination improves
pulmonary health for people with cystic fibrosis (PwCF). However, its impact on objective …

Introduction: The CFTR modulator drug elexacaftor/tezacaftor/ivacaftor (ETI) was shown to
improve CFTR function and clinical symptoms in patients with cystic fibrosis (CF) with at …

Background Cystic fibrosis (CF) lung transplant (LT) recipients may warrant treatment with
elexacaftor/tezacaftor/ivacaftor (ETI) to improve extrapulmonary manifestations of CF. Our …

Background Cystic fibrosis (CF) is a multisystem disease that often requires otolaryngology
care. Individuals with CF commonly have chronic rhinosinusitis but also present with hearing …